ArticleNPJ digital medicine2026
CNet-Cox for interpretable network biomarker discovery and survival risk scoring in precise breast cancer prognosis.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial: Artificial intelligence in multi-omics: advancing tumor metastasis prediction and mechanism analysis.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Biomarker discovery in biomedicine is often cast as feature selection, yet most methods overlook gene co-localization within regulatory interaction networks, yielding isolated biomarkers with limited biological interpretability and clinical translatability. Here, we propose CNet-Cox, a disease-agnostic, Connected Network-regularized Cox proportional hazards framework that incorporates prior network connectivity into sparse feature selection to identify connected prognostic module. Applied to breast cancer, CNet-Cox revealed the network structure of 68 prognostic biomarkers associated with survival on discovery dataset (TCGA, n = 1080) and achieved a concordance index of 0.913 on internal test dataset, outperforming conventional regularized Cox methods. From these network biomarkers, we derived a six-gene prognostic risk score (PRS) and validated its robustness across seven independent bulk transcriptomic datasets (GEO; n = 1602) and a spatial transcriptomics dataset (Visium; 4992 spots). The PRS consistently improved risk stratification (log-rank p < 0.05) and produced concordant predictions with MammaPrint in spatial prognostics (Pearson r = 0.993). Although evaluated in breast cancer, CNet-Cox is readily extensible to other diseases, molecular interaction networks and time-to-event endpoints, providing a generalizable tool for digital pathology and precision oncology. Overall, our comprehensive downstream analyses highlight that CNet-Cox offers a novel network-aware survival model for systematically discovering connected biomarkers and delivering scalable, precise and interpretable risk prediction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.